What is CinDome Pharma?
CinDome Pharma, a key entity within the CinRx portfolio, is a clinical-stage biotechnology firm dedicated to the development of deudomperidone (CIN-102). The company operates at the intersection of pharmaceutical innovation and patient-centric care, specifically targeting the debilitating symptoms of chronic gastroparesis, including nausea and vomiting. By focusing on improving gastric emptying, CinDome Pharma aims to establish a new standard of care for a condition that currently lacks adequate long-term therapeutic options. The company's operational model benefits from the strategic oversight and resource allocation provided by its parent organization, allowing for a streamlined approach to drug development and clinical execution.
How much funding has CinDome Pharma raised?
CinDome Pharma has raised a total of $59M across 1 funding round:
Series B
$59M
Series B (2024): $59M with participation from CinRx and Perceptive Advisors
Key Investors in CinDome Pharma
CinRx
CinRx Pharma is a Cincinnati-based biotech company that employs a unique hub-and-spoke model to identify and accelerate the development of high-impact medicines.
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
What's next for CinDome Pharma?
With the recent influx of capital, CinDome Pharma is poised to intensify its patient enrollment efforts for ongoing clinical trials. The strategic roadmap involves navigating the complexities of late-stage drug development while maintaining a focus on safety and efficacy profiles for CIN-102. Future growth will likely be defined by the successful completion of these trials and the subsequent pursuit of regulatory approval. The company remains committed to its mission of transforming the treatment landscape for gastroparesis, utilizing its current financial stability to bridge the gap between laboratory research and commercial-scale therapeutic delivery. Investors and stakeholders will be closely monitoring the upcoming data readouts as indicators of the firm's long-term value proposition in the competitive biotech sector.
See full CinDome Pharma company page
